Atavistik Bio announced that it has raised an additional $40 million to advance its precision allosteric small molecule therapeutic pipeline.
Mr. Stuart brings more than 25 years of biopharma executive leadership, corporate strategy, and business development experience to guide Atavistik Bios advancing discovery pipelineJeff Goater,...
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Atavistik Bio, a pre-clinical biotechnology company that is leveraging their scalable and systematic platform to identify novel regulatory sites on proteins to restore function in disease, announced the formation of its Scientific Advisory Board (SAB) comprised of distinguished leaders in protein sciences, inborn errors of metabolism, and cancer.